Amneal Makes First Biosimilar Launch With US Bevacizumab
Alymsys Rival To Avastin, Developed By mAbxience, Is Introduced In US
Executive Summary
Amneal says it has “officially entered the US biosimilar market” after introducing its Alymsys biosimilar bevacizumab rival to Avastin. The biosimilar launch represents the first of three expected for Amneal in 2022, following US FDA approvals earlier this year.
You may also be interested in...
Celltrion Goes It Alone With First Solo US Biosimilar Launch
Celltrion is taking a major step forward in the US with its first direct launch of a biosimilar through its own front-end operation. The Korean firm’s Vegzelma rival to Avastin will be looking to compete with multiple other versions of bevacizumab already in the market.
Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.
Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars
Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.